BACKGROUND: Aging is associated with skeletal muscle anabolic resistance (i.e., reduced muscle protein synthesis during anabolic conditions such as hyperaminoacidemia). The results from studies conducted in cell culture systems and animals suggest that both vitamin D and conjugated linoleic acids (CLAs) stimulate muscle protein synthesis. OBJECTIVES: To conduct a randomized, double-blind, placebo-controlled clinical trial to determine the independent and combined effects of dietary vitamin D and CLA supplementation on myofibrillar protein synthesis rates in sedentary older adults. METHODS:Thirty-two sedentary, older adults were randomized to receive either: 1) 2000 IU vitamin D-3 (Vit D) per day; 2) 4000 mg CLA per day; 3) both Vit D (2000 IU/d) and CLA (4000 mg/d); or 4) placebo for 8 wk. Myofibrillar protein synthesis rates were evaluated by using intravenous [ring-2H5]phenylalanine infusion in conjunction with muscle biopsies during basal, postabsorptive conditions and during combined amino acid and insulin infusion before and after the supplementation period. RESULTS: Before the intervention, basal myofibrillar protein synthesis rates were not different among groups (Placebo: 0.033 ± 0.003; Vit D: 0.034 ± 0.002; CLA: 0.029 ± 0.005; Vit D + CLA: 0.038 ± 0.005 %·h-1), and hyperinsulinemia-hyperaminoacidemia increased myofibrillar protein synthesis rates by ∼35%. Compared with placebo, neither Vit D nor CLA nor combined Vit D + CLA supplementation affected the basal myofibrillar protein synthesis rates (placebo: 0.040 ± 0.004%/h; Vit D: 0.044 ± 0.006%/h; CLA: 0.039 ± 0.006%/h; Vit D + CLA: 0.040 ± 0.007%/h) or the hyperinsulinemia-hyperaminoacidemia-induced increase in myofibrillar protein synthesis (percentage increase from basal before and after the interventions: placebo, 30 ± 11 and 36 ± 11; Vit D, 38 ± 8 and 34 ± 10; CLA, 50 ± 14 and 51 ± 16; Vit D + CLA, 29 ± 15 and 35 ± 8). CONCLUSIONS:Vitamin D and/or CLA supplementation, at the doses provided in our study, does not have muscle anabolic effects in sedentary older adults.The study was registered at clinicaltrials.gov (NCT03115775).
RCT Entities:
BACKGROUND: Aging is associated with skeletal muscle anabolic resistance (i.e., reduced muscle protein synthesis during anabolic conditions such as hyperaminoacidemia). The results from studies conducted in cell culture systems and animals suggest that both vitamin D and conjugated linoleic acids (CLAs) stimulate muscle protein synthesis. OBJECTIVES: To conduct a randomized, double-blind, placebo-controlled clinical trial to determine the independent and combined effects of dietary vitamin D and CLA supplementation on myofibrillar protein synthesis rates in sedentary older adults. METHODS: Thirty-two sedentary, older adults were randomized to receive either: 1) 2000 IU vitamin D-3 (VitD) per day; 2) 4000 mg CLA per day; 3) both VitD (2000 IU/d) and CLA (4000 mg/d); or 4) placebo for 8 wk. Myofibrillar protein synthesis rates were evaluated by using intravenous [ring-2H5]phenylalanine infusion in conjunction with muscle biopsies during basal, postabsorptive conditions and during combined amino acid and insulin infusion before and after the supplementation period. RESULTS: Before the intervention, basal myofibrillar protein synthesis rates were not different among groups (Placebo: 0.033 ± 0.003; VitD: 0.034 ± 0.002; CLA: 0.029 ± 0.005; VitD + CLA: 0.038 ± 0.005 %·h-1), and hyperinsulinemia-hyperaminoacidemia increased myofibrillar protein synthesis rates by ∼35%. Compared with placebo, neither VitD nor CLA nor combined VitD + CLA supplementation affected the basal myofibrillar protein synthesis rates (placebo: 0.040 ± 0.004%/h; VitD: 0.044 ± 0.006%/h; CLA: 0.039 ± 0.006%/h; VitD + CLA: 0.040 ± 0.007%/h) or the hyperinsulinemia-hyperaminoacidemia-induced increase in myofibrillar protein synthesis (percentage increase from basal before and after the interventions: placebo, 30 ± 11 and 36 ± 11; VitD, 38 ± 8 and 34 ± 10; CLA, 50 ± 14 and 51 ± 16; VitD + CLA, 29 ± 15 and 35 ± 8). CONCLUSIONS:Vitamin D and/or CLA supplementation, at the doses provided in our study, does not have muscle anabolic effects in sedentary older adults.The study was registered at clinicaltrials.gov (NCT03115775).
Authors: P W Watt; Y Lindsay; C M Scrimgeour; P A Chien; J N Gibson; D J Taylor; M J Rennie Journal: Proc Natl Acad Sci U S A Date: 1991-07-01 Impact factor: 11.205
Authors: Isabel Marantes; Sara J Achenbach; Elizabeth J Atkinson; Sundeep Khosla; L Joseph Melton; Shreyasee Amin Journal: J Bone Miner Res Date: 2011-12 Impact factor: 6.741
Authors: Romy Conzade; Eva Grill; Heike A Bischoff-Ferrari; Uta Ferrari; Alexander Horsch; Wolfgang Koenig; Annette Peters; Barbara Thorand Journal: Calcif Tissue Int Date: 2019-05-08 Impact factor: 4.333
Authors: Hennie C J P Janssen; Marielle H Emmelot-Vonk; Harald J J Verhaar; Yvonne T van der Schouw Journal: J Am Med Dir Assoc Date: 2013-06-27 Impact factor: 4.669
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: Stephan van Vliet; Sarah K Skinner; Joseph W Beals; Brandon A Pagni; Hsin-Yu Fang; Alexander V Ulanov; Zhong Li; Scott A Paluska; Michael Mazzulla; Daniel W D West; Daniel R Moore; Kenneth R Wilund; Nicholas A Burd Journal: Kidney Int Rep Date: 2018-08-17
Authors: Konstantinos Prokopidis; Panagiotis Giannos; Konstantinos Katsikas Triantafyllidis; Konstantinos S Kechagias; Jakub Mesinovic; Oliver C Witard; David Scott Journal: J Cachexia Sarcopenia Muscle Date: 2022-03-08 Impact factor: 12.063